MetaCap

Verastem Inc. (VSTM)

NASDAQ: VSTMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

6.33-0.53 (-7.73%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

VSTM stock chart

Technical analysis

Key statistics

All statistics
Market cap
$797.67M
EPS (TTM)
-$1.84
52-week range
3.43 – 10.82
Day range
6.25 – 6.82
Volume / Avg
3.24M / 3.53M
Beta
—

52-week range

$3.43$10.82

VSTM stock today

Verastem (VSTM) closed at $6.33 on Nov 20, down 7.73% (-$0.53), versus the S&P 500's 3.70% decline. At this level, VSTM sits in the middle of its 52-week range of $3.43 to $10.82: 41.5% below the high, set on Nov 26, 2025 and 84.5% above the low. VSTM is down 18.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 36.7%.

Verastem has posted a net loss over the last twelve months (EPS of -$1.84), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Verastem

Company profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Daniel W. Paterson
Headquarters
Needham, MA
Employees
102
IPO year
2012

Financial highlights

Full financials

In fiscal 2025, Verastem generated $30.9 million in revenue, up 209.1% from fiscal 2024. Verastem reported a net loss of $209.5 million, compared with a loss of $130.6 million a year earlier. Operating margin was -550.3%.

Verastem annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$30.91M$10.00M—$2.60M$2.05M
Growth+209.14%——+26.45%-97.68%
Net income$-209.47M$-130.64M$-87.37M$-73.81M$-71.20M
EPS (diluted)$-3.02$-3.66$-3.96$-4.57$-4.90

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$17.22+172.04%

  • Strong buy 1
  • Buy 9
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $24.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-1.35 vs $-0.44
Surprise
-206.82%

VSTM news

All VSTM news

Verastem peers

Health Care sector
VSTM peer companies
CompanyPrice% ChgMarket capCompare
SNDXSyndax Pharmaceuticals Inc.8.72-4.49%$785.05Mvs VSTM
CRVSCorvus Pharmaceuticals Inc.9.67-3.40%$815.69Mvs VSTM
PHARPharming Group N.V. ADS11.54-5.10%$816.78Mvs VSTM
IRWDIronwood Pharmaceuticals Inc. Class A4.70-0.21%$778.09Mvs VSTM
COLLCollegium Pharmaceutical Inc.24.72-1.94%$768.18Mvs VSTM
ORICOric Pharmaceuticals Inc.7.36-4.42%$764.94Mvs VSTM
RIGLRigel Pharmaceuticals Inc.40.09-2.67%$754.89Mvs VSTM
ARDXArdelyx Inc.2.99-2.29%$751.60Mvs VSTM

Indexes, lists and sector

Verastem stock FAQ

What is Verastem's stock price today?

VSTM last traded at $6.33 as of Nov 20, 4:00 PM EST, down 7.73% on the day. Prices are delayed at least 15 minutes.

Does Verastem pay a dividend?

No. Verastem does not currently pay a regular cash dividend.

Who is Verastem's CEO?

Mr. Daniel W. Paterson is the chief executive officer of Verastem Inc., which has about 102 employees.

Has VSTM ever split its stock?

Yes. The most recent VSTM stock split was a 1-for-12 split on Jun 1, 2023.

What is the VSTM 52-week high?

The 52-week high for VSTM is $10.82 and the 52-week low is $3.43. The stock is currently 41.5% below its high.

Compare VSTM